Loading...
Market
What will be the outcome of UniQure's AMT-130 Phase I/II trial results by end of 2024?
2
Resolution / Starting Odds
Highly positive • 25%
Moderately positive • 25%
Neutral • 25%
Negative • 25%
UniQure press releases and clinical trial results
Story
UniQure Stock Surges 60% on Positive AMT-130 Huntington’s Gene Therapy Data
Jul 9, 2024, 02:51 PM
UniQure has announced positive interim data from its Phase I/II trials of AMT-130, a gene therapy for Huntington’s disease. The data demonstrated a statistically significant, dose-dependent slowing of disease progression, with patients receiving high-dose AMT-130 showing an 80% reduction in the progression of the disease in the composite Unified Huntington’s measure. Following this announcement, uniQure's stock surged by 60%, reflecting investor optimism about the potential of this one-time therapy. The stock saw a pre-market increase of 27% and continued to rise throughout the day.
View original story
Similar markets
Less than 50% efficacy • 25%
50-69% efficacy • 25%
70-89% efficacy • 25%
90% or higher efficacy • 25%
Yes • 50%
No • 50%
Phase III trial initiation • 25%
FDA accelerated approval • 25%
New interim data release • 25%
Other milestone • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
FDA • 33%
EMA • 33%
Both • 34%